RANDOMIZED PLACEBO-CONTROLLED TRIAL OF RECOMBINANT INTERLEUKIN-2 IN CHRONIC UREMIC PATIENTS WHO ARE NONRESPONDERS TO HEPATITIS-B VACCINE

被引：58

作者：

JUNGERS, P

DEVILLIER, P

SALOMON, H

CERISIER, JE

COUROUCE, A

机构：

[1] ROUSSEL UCLAF,DEPT IMMUNOL,ROMAINVILLE,FRANCE

[2] PASTEUR MERLEUX,SERUMS & VACCINS,DEPT MED,MARNES COQUETTE,FRANCE

[3] INST NATL TRANSFUS SANGUINE,F-75015 PARIS,FRANCE

来源：

LANCET | 1994年 / 344卷 / 8926期

关键词：

D O I：

10.1016/S0140-6736(94)92829-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Natural interleukin-2 at low dose has been reported to overcome the non-responsiveness of patients with chronic uraemia to hepatitis B vaccine. Therefore, we revaccinated 52 previous such non-responders (24 on maintenance dialysis) with 20 mu g of recombinant preS2-containing hepatitis B vaccine with human recombinant interleukin-2 (1 MU) or placebo (randomly allocated). Seroconversion rates (74 vs 80%, respectively) and proportion of patients who elicited anti-HBs titres of 10 mlU/mL or more (56 vs 68%) were similar in both groups. Our results do not confirm local injection of interleukin-2 as an effective immunoadjuvant to hepatitis B vaccine in uraemic patients.

引用

页码：856 / 857

页数：2

共 10 条

[1]

BENHAMOU E, 1984, CLIN NEPHROL, V21, P143

[2]

BLANKENSTIJN PJ, 1993, J AM SOC NEPHROL, V4, pA334

[3]

CROSNIER J, 1981, LANCET, V1, P797

[4] HEPATITIS-B VACCINATION AND INTERLEUKIN-2 RECEPTOR EXPRESSION IN CHRONIC-RENAL-FAILURE [J].